Impact of two-session fecal microbiota transplantation on minimal hepatic encephalopathy in cirrhosis

Table 3 Adverse events over 3 months follow-up, n (%)

	Overall (n = 122)	FMT (n = 60)	Lactulose (n = 62)	P value
Any adverse events1	58 (47.5)	32 (53.3)	26 (41.9)	0.21
Bloating	18 (14.8)	3 (5.0)	15 (24.2)	< 0.01
Abdominal pain	16 (13.1)	7 (11.7)	9 (14.5)	0.64
Diarrhoea	11 (9.0)	6 (10.0)	5 (8.1)	0.71
Vomiting	4 (3.3)	3 (5.0)	1 (1.6)	0.36
Malaise	9 (7.4)	7 (11.7)	2 (3.2)	0.09
Fever	17 (13.9)	12 (20.0)	5 (8.1)	0.06
Cough	3 (2.5)	3 (5.0)	0	0.12
Constipation	7 (5.7)	7 (11.7)	0	< 0.01
Altered taste	1 (0.8)	1 (1.7)	0	0.49
Death	3 (2.5)	2 (3.3)	1 (1.6)	0.62
Overt HE	3 (2.5)	2 (3.3)	1 (1.6)	1.00
Sepsis	7 (5.7)	5 (8.3)	2 (3.2)	0.13
Pneumonia	2 (1.6)	2 (3.3)	0
Urosepsis	2 (1.6)	1 (1.7)	1 (1.6)
Cellulitis	1 (0.8)	0	1 (1.6)
Gastrointestinal	2 (1.6)	2 (3.3)	0

¹Total number of adverse events may not be additive, as a single patient may experience more than one event.

FMT: Fecal microbiota transplantation; HE: Hepatic encephalopathy.